Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022
Introduction Since the first description of Thrombotic Thrombocytopenic Purpura, caused by a severe deficiency of ADAMTS13, plasma exchange and immunosuppression have become standard treatments, allowing to decrease its high mortality rate. Prospective records of Thrombotic Thrombocytopenic Purpura...
Saved in:
| Main Authors: | Daniel Cathalifaud, Jean-Paul Manríquez, Benjamín Rodríguez, Gonzalo Eymin, Benjamín Sanfuentes, Joel Castellano, Andrés Valenzuela |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medwave Estudios Limitada
2025-07-01
|
| Series: | Medwave |
| Subjects: | |
| Online Access: | https://www.medwave.cl/investigacion/estudios/3002.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical presentation and treatment of thrombotic thrombocytopenic purpura - analysis of recent diagnostic and therapeutic methods
by: Jan Szwech, et al.
Published: (2025-03-01) -
Thrombotic Thrombocytopenic Purpura as a Rare Etiopathogenetic Cause of Cerebral Infarction and Extracerebral Thrombosis
by: А. R. Аvidzba, et al.
Published: (2021-08-01) -
Pancreatic Cancer Presenting with Thrombotic Thrombocytopenic Purpura: A Case Report and Review of Literature
by: Yeh-Chin Wang, et al.
Published: (2025-04-01) -
COVID-19 and thrombotic microangiopathy
by: E. V. Sluhanchuk, et al.
Published: (2022-01-01) -
Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report
by: Judith Schimpf, et al.
Published: (2025-04-01)